Texas Biotech, SmithKline deal

The companies will co-develop and market Novastan ( argatroban), TXB's direct inhibitor of thrombin, as anticoagulant therapy in patients

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE